3-(1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol | 501362-82-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-(1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol
• 英文别名: (1R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl-methoxy]cyclohexan-1-ol；(1R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexan-1-ol；(+)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl-methoxy]cyclohexanol；3-(1R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazol4-ylmethoxy]cyclohexanol；cis-3S-(2-p-tolyl-5-methyloxazol-4-ylmethoxy)cyclohexan-1R-ol；(1r,3s)-3-[2-(4-Fluorophenyl)-5-methyloxazol4-ylmethoxy]cyclohexanol；(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-1,3-oxazol-4-yl]methoxy]cyclohexan-1-ol
• CAS: 501362-82-9
• 化学式: C₁₇H₂₀FNO₃
• 分子量: 305.349
• InChiKey: JEMQSYWUSRUZQU-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  55.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol 、 benzyl 2-bromomethyl-6-methylbenzoate 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以90%的产率得到benzyl 2-methyl-6-[(1R,3S)-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyloxymethyl]benzoate
  参考文献：
  名称：

  METHOD FOR THE PRODUCTION OF DIARYLCYCLOALKYL DERIVATIVES

  摘要：

  本发明涉及一种制备公式（I）的二芳基环烷基衍生物的方法，其中各自的R基取代基如本文所定义。公式（I）化合物是过氧化物酶体增殖物激活受体（PPAR激活剂），在治疗多发性硬化症、帕金森病、精神障碍等中枢神经系统疾病和疾病方面非常有用。本发明提供了一种新的制备公式（I）的PPAR激活剂的方法，该方法不具有先前技术中已知的缺点。特别是，提供了一种方法，可以在不需要后续手性色谱的情况下以适当的对映选择性制备公式（I）的PPAR激活剂，即高对映选择性。

  公开号：

  US20070197614A1
• 作为产物：
  描述：

  (1R,3S)-3-[2-(4-fluorophenyl)-5-methyloxazyol-4-ylmethoxy]cyclohexyl acetate 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 生成 3-(1R,3S)-cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexanol
  参考文献：
  名称：

  Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals

  摘要：

  芳基环烷基取代的烷基酸衍生物，其制备方法及其作为药物的用途。该发明涉及芳基环烷基取代的烷基酸衍生物及其生理可接受的盐和生理功能衍生物。所描述的化合物为式I，其中基团如所定义，以及其生理可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢障碍、葡萄糖利用障碍以及胰岛素抵抗相关的疾病。

  公开号：

  US20040209920A1

文献信息

• Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20040122069A1

  公开（公告）日：2004-06-24

  Diarylcycloalkyl derivatives and their physiologically acceptable salts and physiologically functional derivatives are disclosed. The compounds include those of formula I, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metabolism, of type II diabetes, and of syndrome X.

  披露了二芳基环烷基衍生物及其生理上可接受的盐和生理功能衍生物。这些化合物包括式I,1中定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物通常具有降脂和/或三酸甘油酯降低作用，并且适用于例如治疗脂质代谢紊乱、II型糖尿病和X综合征等疾病。
• Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040209931A1

  公开（公告）日：2004-10-21

  Process for preparing the enantiomeric forms of cis-configured 1,3-cyclohexanediol derivatives A process is described for preparing chiral, nonracemic, cis-configured 1,3-disubstituted cyclohexanols of the formula (I) 1 where the radicals are as defined, by means of enzymatic optical resolution.

  描述了一种用于制备手性、非对映体、顺式配置的1,3-二取代环己醇衍生物的过程，其化学式为(I)，其中基团如所定义，通过酶促光学分辨的方法。
• Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040198786A1

  公开（公告）日：2004-10-07

  Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, 1 in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.

  环烷基衍生物具有生物等效羧酸基团，其制备方法及其作为药物的用途。本发明涉及具有生物等效羧酸基团的环烷基衍生物及其生理上可接受的盐和生理功能衍生物。所描述的化合物具有下式1,1中所定义的基团，以及它们的生理上可接受的盐和制备方法。这些化合物适用于治疗和/或预防脂肪酸代谢紊乱和葡萄糖利用障碍以及胰岛素抵抗相关的紊乱。
• ARYLYCLOALKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
  申请人：Stapper Christian

  公开号：US20080167354A1

  公开（公告）日：2008-07-10

  The invention relates to arylcycloalkyl-substituted alkanoic acid derivatives and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula I, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparation. The compounds are suitable, for example, for the treatment and/or prevention of disorders of the fatty acid metabolism and glucose utilization disorders and also disorders in which insulin resistance is involved.

  该发明涉及芳基环烷基取代的脂肪酸衍生物及其生理上可接受的盐和生理功能衍生物。所描述的是公式I中的化合物，其中基团如定义的那样，以及它们的生理上可接受的盐和制备它们的过程。这些化合物适用于治疗和/或预防脂肪酸代谢障碍和葡萄糖利用障碍以及胰岛素抵抗有关的疾病。
• VERFAHREN ZUR HERSTELLUNG DER ENANTIOMEREN FORMEN VON CIS-KONFIGURIERTEN 1,3-CYCLOHEXANDIOL-DERIVATEN
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1599433A1

  公开（公告）日：2005-11-30